TLDRs
- Hims & Hers rallies on FDA peptide regulation optimism and strong investor sentiment.
- Subscriber growth above 2.5 million continues to drive revenue expansion momentum.
- Peptide regulatory review may unlock new telehealth revenue opportunities ahead.
- Healthcare tech stocks diverge as Hims leads while peers lag behind.
Hims & Hers Health continued its strong upward momentum in Monday trading, extending a multi-day rally as investors increasingly price in potential regulatory tailwinds from the U.S. Food and Drug Administration (FDA).
The stock surged another 8.9% intraday, reinforcing a broader weekly advance that has already pushed gains to nearly 50% over the past week.
The latest optimism centers on scheduled FDA meetings in late July, where officials are expected to evaluate whether compounding pharmacies should be permitted to manufacture certain peptide-based treatments. These compounds are widely associated with applications in obesity management, sleep support, and regenerative therapies, areas closely aligned with Hims & Hers’ expanding digital health model.
Hims & Hers Health, Inc., HIMS
Peptide Opportunity Narrative Builds
Market analysts have increasingly pointed to the FDA discussion as a potential turning point for companies operating in personalized and compounding medicine. Hims & Hers, which acquired a California-based peptide production facility last year, stands out as one of the most exposed players in this emerging regulatory shift.
Investment commentary from major research desks has highlighted the potential upside. Some analysts describe the regulatory review as creating “optionality” for new revenue channels, particularly if telehealth firms are allowed to scale peptide-related offerings under expanded guidelines.
Company leadership has also signaled strategic interest in this segment. Management has indicated ongoing efforts to align operations with regulatory developments while exploring broader access to peptide-based treatments across its digital healthcare platform.
Subscriber Growth Powers Expansion
Beyond regulatory catalysts, Hims & Hers continues to benefit from strong underlying business momentum. The company reported fourth-quarter revenue of $617.8 million, reflecting a 28% year-over-year increase. Subscriber numbers have now surpassed 2.5 million, underscoring continued adoption of its direct-to-consumer healthcare model.
This expansion has been supported by rising demand for telehealth services, particularly in weight management, dermatology, and mental health offerings. The company also closed 2025 with more than 2.5 million active users, a key milestone that reinforces recurring revenue strength.
Looking ahead, Hims & Hers has projected full-year 2026 revenue between $2.7 billion and $2.9 billion, signaling confidence in continued scale despite regulatory and operational uncertainties.
Mixed Sector Performance Persists
While Hims & Hers has been the standout performer in the healthcare technology space, broader sector trends remain uneven. Competitors such as Omnicell and Privia Health have posted comparatively muted stock reactions despite generally solid financial results across the group.
Omnicell, in particular, has faced pressure following weaker bookings and slower product momentum, even as it reported modest revenue growth. Privia Health has performed more consistently, delivering double-digit revenue expansion and meeting or exceeding internal guidance across key metrics.
The divergence highlights a growing split within healthcare technology stocks, where investor enthusiasm is increasingly concentrated in companies with stronger consumer-facing growth narratives and exposure to emerging regulatory opportunities.
Earnings Focus Ahead of May Reports
Attention is now turning toward upcoming earnings announcements, which could further shape sentiment across the sector. Hims & Hers is scheduled to report results on May 11, while peers Privia Health and Omnicell will release earnings earlier in the month.
For Hims & Hers, expectations remain elevated following its recent rally. Investors will closely watch subscriber growth trends, margin performance, and any updates on regulatory developments tied to peptide-based treatments.
With momentum already strong and policy uncertainty acting as both a risk and opportunity, the coming weeks may prove decisive in determining whether the stock’s recent surge marks a temporary spike, or the beginning of a longer-term revaluation.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
